Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.31)
# 2,498
Out of 4,786 analysts
48
Total ratings
45.83%
Success rate
7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $12.73 | +64.96% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $0.24 | +4,130.12% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $0.68 | +782.35% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $52.97 | -32.04% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $10.11 | +394.56% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $34.03 | +370.17% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $8.49 | +371.14% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $36.21 | +189.98% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $63.81 | -57.69% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $88.51 | +12.98% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.55 | +3,125.81% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $270 | $3.74 | +7,119.25% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $288 | $5.07 | +5,580.47% | 2 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.24 | +12,803.23% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $12.73
Upside: +64.96%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $0.24
Upside: +4,130.12%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $0.68
Upside: +782.35%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $52.97
Upside: -32.04%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $10.11
Upside: +394.56%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $34.03
Upside: +370.17%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $8.49
Upside: +371.14%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $36.21
Upside: +189.98%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $63.81
Upside: -57.69%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $88.51
Upside: +12.98%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $1.55
Upside: +3,125.81%
Nov 5, 2019
Maintains: Buy
Price Target: $225 → $270
Current: $3.74
Upside: +7,119.25%
Aug 15, 2018
Maintains: Buy
Price Target: $264 → $288
Current: $5.07
Upside: +5,580.47%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.24
Upside: +12,803.23%